Fulcrum Therapeutics (NASDAQ:FULC) has filed an IND
with the FDA seeking sign-off for a late-stage clinical study
evaluating lead drug losmapimod in hospitalized COVID-19 patients.
According to President & CEO Robert Gould,
Ph.D., prior studies in other diseases showed the drug’s ability to
reduce inflammatory proteins like IL-6 and C-reactive protein (CRP) that
are associated with a poor prognosis.
On the working capital front, it has closed its
$68.5M private placement of stock (~4M common shares at $17). Its
current balance of quick assets should be sufficient to fund operations
into Q1 2022.
Management hosted a conference call today at 8:30 am ET to discuss recent developments.
https://seekingalpha.com/news/3581828-fulcrum-therapeutics-to-test-losmapimod-in-covidminus-19
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.